167 related articles for article (PubMed ID: 33649621)
21. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
[TBL] [Abstract][Full Text] [Related]
22. Fournier's gangrene and SGLT2 inhibitors: A case study.
García-García A; Galeano-Valle F; Nuevo-González JA; Demelo-Rodríguez P
Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(6):423-425. PubMed ID: 32354633
[No Abstract] [Full Text] [Related]
23. [Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].
Breuer TGK; Kampmann K; Wutzler A; Steinfort C; Uhl W; Schmidt WE; Meier JJ
Internist (Berl); 2018 Mar; 59(3):282-287. PubMed ID: 28864828
[TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin for the treatment of type 1 diabetes mellitus.
Pafili K; Maltezos E; Papanas N
Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
[TBL] [Abstract][Full Text] [Related]
25. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
26. Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
Sayed N; Abdalla O; Kilany O; Dessouki A; Yoshida T; Sasaki K; Shimoda M
J Vet Med Sci; 2020 Apr; 82(4):467-474. PubMed ID: 32161237
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
28. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
30. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
31. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
32. Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Masuda D; Yamashita S
J Atheroscler Thromb; 2020 Jul; 27(7):637-638. PubMed ID: 32009076
[No Abstract] [Full Text] [Related]
33. Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction.
Miyauchi T
Daru; 2020 Jun; 28(1):419-421. PubMed ID: 32103459
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
35. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
36. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Yabiku K; Nakamoto K; Tsubakimoto M
J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
[TBL] [Abstract][Full Text] [Related]
37. Sodium glucose co-transporter 2 inhibitors in heart failure therapy.
Çavuşoğlu Y; Altay H; Cahn A; Celik A; Demir S; Kılıçaslan B; Nalbantgil S; Raz I; Temizhan A; Yıldırımtürk Ö; Yılmaz MB
Turk Kardiyol Dern Ars; 2020 Apr; 48(3):330-354. PubMed ID: 32281958
[No Abstract] [Full Text] [Related]
38. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
39. Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Elbeddini A; Tayefehchamani Y; Davey M; Gallinger J; Hooda N; Aly A; Erickson D; Lee S
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33526523
[TBL] [Abstract][Full Text] [Related]
40. [Ketogenic diet as a trigger for diabetic euglycaemic ketoacidosis in a patient under treatment with iSGLT2].
Nubiola A; Ternianov A; Remolins I
Hipertens Riesgo Vasc; 2020; 37(1):39-41. PubMed ID: 31734176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
